← Back to Search

Integrated Diabetes Care for Type 2 Diabetes

N/A
Waitlist Available
Research Sponsored by The University of Texas Medical Branch, Galveston
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients have a BMI equal to or >25 (23, if Asians)
Patients diagnosed with type 2 diabetes
Must not have
Ages <13 or >84
Previous diagnosis of type 1 diabetes
Timeline
Screening 3 weeks
Treatment Varies
Follow Up every session through study completion, an average of 1 year

Summary

This trial is testing an integrated model of care for patients with type 2 diabetes, to see if it improves diabetes self-management outcomes.

Who is the study for?
This trial is for people aged 13-84 with type 2 diabetes, who have a Hemoglobin A1c value of at least 7% and a BMI of at least 25 (or 23 for Asians). It's not suitable for those unable to commit to a year-long study, planning to move away from the area, pregnant women, prisoners, or anyone with conditions that could affect their survival.
What is being tested?
The study compares standard diabetes care against an integrated model called iDSMES. Participants in the iDSMES group will receive comprehensive support including dietary counseling and various therapies aimed at improving self-management of diabetes over one year.
What are the potential side effects?
Since this trial focuses on education and lifestyle management rather than medication, side effects are minimal but may include discomfort from lifestyle changes or stress related to participation in the educational program.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My BMI is 25 or higher (23 if I'm Asian).
Select...
I have been diagnosed with type 2 diabetes.
Select...
I am between 13 and 84 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am younger than 13 or older than 84.
Select...
I have been diagnosed with type 1 diabetes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~every session through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and every session through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change from baseline HbA1c
Secondary study objectives
Change from baseline blood pressure
Change from baseline diabetes distress
Change from baseline frequency of emergency care visits for treatment of T2-related issues
+14 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: iDSMESActive Control1 Intervention
Eligible study subjects randomized to the intervention arm will receive: A. Intensive Diabetes Self-Management, Education, and Support (iDSMES). Participants will be enrolled in groups in a virtual or in-person setting with their lifestyle coach, in this one-year educational program B. Services addressing Social Determinants of Health All study subjects will have their data collected at time points around baseline, 6 months and 12 months from consenting including glycemic control, hypertension management, dyslipidemia management, prevention or management of complications, healthcare outcomes, lifestyle change outcomes, patient-centeredness outcomes, Secondary diabetes self-management behaviors, self-efficacy in managing diabetes, diabetes distress, and Morisky Green Levine Medication Adherence Scale.
Group II: Standard of CarePlacebo Group1 Intervention
Eligible study subjects randomized to the intervention arm will receive standard of care offered to patients with diabetes.

Find a Location

Who is running the clinical trial?

The University of Texas Medical Branch, GalvestonLead Sponsor
250 Previous Clinical Trials
56,608 Total Patients Enrolled

Media Library

iDSMES Clinical Trial Eligibility Overview. Trial Name: NCT05097534 — N/A
Type 2 Diabetes Research Study Groups: iDSMES, Standard of Care
Type 2 Diabetes Clinical Trial 2023: iDSMES Highlights & Side Effects. Trial Name: NCT05097534 — N/A
iDSMES 2023 Treatment Timeline for Medical Study. Trial Name: NCT05097534 — N/A
~4 spots leftby Dec 2024